Herantis Pharma Plc.

📍 Espoo, Finland🗓 Founded 2008👥 20 employees💰 Last funded Apr 2021
Biotechnology Research🌐 herantis.com
Website LinkedIn
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096, is an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the parent CDNF protein. It combines the compelling mechanism of action of the CDNF protein with the convenience of subcutaneous administration. The ongoing Phase 1a clinical study will assess safety, tolerability, and blood-brain barrier penetration of subcutaneously administered HER-096. Top-line data is expected by the end of 2023. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
2008
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
Denmark
1
Frequently asked questions
Who invested in Herantis Pharma Plc.?
Herantis Pharma Plc. has 1 investors on record on gritt.io.
When did Herantis Pharma Plc. last raise funding?
The most recent investment in Herantis Pharma Plc. recorded on gritt.io was in April 2021.
When was Herantis Pharma Plc. founded?
Herantis Pharma Plc. was founded in 2008.
What industry is Herantis Pharma Plc. in?
Herantis Pharma Plc. operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Herantis Pharma Plc. based?
Herantis Pharma Plc. is headquartered in Espoo, Finland.